28 January 2021, h 15.00 (Zoom meeting)
Speaker: Prof. Darren Roblyer, Biomedical Optical Technologies Lab, Department of Biomedical Engineering – Boston University, Boston, MA, USA
Organizers: Valentina Bello, Prof. Sabina Merlo; PhD Coordinators: Prof. Paolo Di Barba, Prof. Silvana Quaglini, Prof. Piero Malcovati
Despite an ever-increasing set of chemotherapeutic, targeted, and immunotherapies for patients suffering from cancer, individual responses to treatment remain highly variable. Standard-of-care imaging modalities (MRI, PET-CT, etc.) have limited ability to detect response and resistance early and often during treatment due to access, cost, and safety concerns. In order to move towards truly adaptive and personalized therapeutic regimens, near real-time in vivo measurements of key response metrics are needed. In this talk, I will discuss how label-free diffuse optical technologies are moving us towards real-time personalized therapy for cancer. I will also discuss the technological advancements my group is making to expand optical contrasts and access to patients. This includes the development of wearable probes, ultra-fast frequency domain diffuse optics, and short-wave infrared quantitative imaging. We are using these techniques in both the preclinical and clinical settings to interrogate the molecular, metabolic, and hemodynamic state of tumors in new ways, paving the way for a new set of non-invasive label-free optical imaging markers for treatment response monitoring in the clinic.